Mirador Therapeutics

What Mirador Therapeutics does

Mirador Therapeutics is a clinical-stage precision medicine company founded in March 2024 and headquartered at 4902 Headquarters Point, Suite 300, San Diego, California. The company is developing first-in-class and best-in-class therapies for immune-mediated inflammatory and fibrotic (I&I) diseases — specifically Crohn's disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis — targeting patients who are unresponsive, intolerant, or lose response to existing therapies. Mirador has no commercial products and generates no product revenue; its economics are entirely R&D-driven, funded by venture capital.

The company's central technology asset is Mirador360, a proprietary end-to-end precision discovery and development engine that integrates multiomics, clinical, and molecular data from more than 2.5 million I&I patient profiles with advanced analytics and AI/ML to identify novel therapeutic targets, prioritize optimal combination therapies, and stratify patient populations for clinical development. The engine supports the company's multi-asset clinical pipeline, with management committing to 10 or more clinical readouts by year-end 2027.

Mirador operates as a pre-commercial biotech with a typical clinical-development business model: assets will ultimately reach patients through clinical trials and, upon regulatory approval, through traditional pharmaceutical distribution. The company is controlled by founder, Chairman and CEO Mark C. McKenna — formerly Chairman, President and CEO of Prometheus Biosciences, which was acquired by Merck for $10.8 billion in June 2023 — and staffed across the C-suite by former Prometheus executives in CSO, CMO, CLO, CAO, and Chief Geneticist roles. Mirador has raised over $650 million since launch across a $400M Series A (March 2024, led by ARCH Venture Partners) and a $250M Series B (Q3 2025, with new investors T. Rowe Price, Adage Capital Partners, and Fidelity).

Name

Mirador Therapeutics

Legal name

Mirador Therapeutics, Inc.

Website

https://miradortx.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Mirador Therapeutics is a clinical-stage precision medicine company developing first-in-class and best-in-class therapies for immune-mediated inflammatory and fibrotic diseases (Crohn's, UC, RA, IPF) using its proprietary Mirador360 AI-enabled discovery engine.

Ownership category

akta.pro rank

Product category

Precision Medicine

NAICS

Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

akta.pro secondary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

Keywords

• Precision medicine
• Immune-mediated diseases
• Inflammatory diseases therapy
• Fibrotic diseases treatment
• Drug discovery platform

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Others

Distribution channels1 record

Marketing channels4 records

Core offering

Mirador Therapeutics develops first-in-class and best-in-class precision medicines for immune-mediated inflammatory and fibrotic diseases. Its core asset is the proprietary Mirador360™ engine, which integrates multi-modal patient data from over 2.5 million profiles with AI and advanced analytics to identify novel targets, prioritize combination therapies, and stratify patient populations. The company is advancing a clinical pipeline targeting Crohn's disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis.

Product overview

Mirador Therapeutics is a clinical-stage precision medicine company that operates as a unified platform focused on developing first-in-class and best-in-class therapies for immune-mediated inflammatory and fibrotic diseases. The company's core offering is the Mirador360™ (M360) precision discovery and development engine, which serves as the central technology platform integrating multi-modal patient data, AI-driven analytics, and genetic insights to power the company's therapeutic pipeline. The platform enables rapid target discovery and validation, patient stratification, and combination therapy prioritization across multiple clinical programs targeting Crohn's disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis.

Differentiator

Problem solved

Functional benefit

Brands

• Mirador360: Proprietary end-to-end precision discovery and development engine that leverages advances in human genetics, cutting-edge biology, multi-modal data, AI and advanced analytics to identify novel targets, select optimal combination therapies and pinpoint patients most likely to benefit from treatment.

Products and services

• Mirador360™ Precision Development Engine Mirador360™ is Mirador Therapeutics' proprietary end-to-end precision discovery and development engine. It harmonizes data from over 2.5 million patient molecular profiles across immunology and inflammation diseases, integrating multi-modal data, advanced analytics, and AI/ML to discover and validate genetic associations with immuno-fibrotic diseases, identify novel therapeutic targets, elucidate target-target interactions and optimal target-target pairs for combination therapies, develop diagnostics, and stratify heterogeneous patient populations for clinical development.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature1 record

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Roivant Sciences: Clinical-stage platform biotech with multiple Vants spanning immunology and inflammation (e.g., Priovant, Telavant). Comparable model of using data-driven development and partnership economics to advance specialty therapeutics.
• Takeda Pharmaceutical: Owns Entyvio (UC/Crohn's) and has expanded its GI/inflammation pipeline through acquisitions (Maverix, Nimbus-Lakshmi). Direct competitor in IBD and adjacent fibrotic indications.
• Eli Lilly: Owns Taltz (psoriatic disease), Olumiant (RA), and is rapidly expanding its immunology footprint through internal pipeline and acquisitions. Competitor across RA, IBD, and fibrotic disease spaces.
• Sanofi: Dupixent franchise leader in I&I (atopic dermatitis, asthma, eosinophilic esophagitis, prurigo nodularis) and a Series A investor in Mirador via Sanofi Ventures. Strategic comparator and potential future partner.
• Bristol Myers Squibb: Major I&I player with Zeposia (UC), Sotyktu (psoriasis), and a deepening immunology pipeline including TYK2 and IRAK4 programs. Direct competitive overlap in IBD, RA, and adjacent indications.
• AbbVie: Owns Skyrizi and Rinvoq — the I&I franchise leaders in IBD/psoriasis/RA — and is the dominant commercial competitor for any precision immunology entrant targeting the same indications.
• Merck & Co. Owns the anti-TL1A program acquired from Prometheus for $10.8B and is the most direct head-to-head competitor for Mirador's likely next-generation pipeline assets.
• Incyte Corporation: Mid-cap biotech with a deep immunology pipeline including ruxolitinib cream and multiple IL-15/IL-23 programs. Comparable as a focused inflammation/immunology developer with both approved and clinical-stage assets.

Direct peers

• Ventyx Biosciences: Clinical-stage immunology-focused biotech developing oral therapies for I&I diseases, co-founded/led by Mirador's Chief Strategy Officer William Sandborn. Directly comparable by indication (IBD/RA), stage, and approach.
• Prometheus Biosciences (acquired by Merck): Mirador's direct predecessor company, founded by the same executives, focused on precision immunology and the anti-TL1A program now owned by Merck. Provides the clearest comparable for Mirador's pipeline approach and exit trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks3 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mirador-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds4 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mirador Therapeutics